Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Down to $18.74

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) shares gapped down prior to trading on Thursday . The stock had previously closed at $18.74, but opened at $18.17. Calliditas Therapeutics AB (publ) shares last traded at $18.41, with a volume of 688 shares trading hands.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $50.00 price target on shares of Calliditas Therapeutics AB (publ) in a report on Thursday, February 22nd.

Calliditas Therapeutics AB (publ) Stock Performance

The company has a debt-to-equity ratio of 2.89, a quick ratio of 3.08 and a current ratio of 3.13. The stock has a 50-day moving average price of $21.20 and a 200 day moving average price of $20.59.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) last issued its quarterly earnings results on Wednesday, February 21st. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.02. The company had revenue of $42.45 million for the quarter, compared to the consensus estimate of $36.24 million. Calliditas Therapeutics AB (publ) had a negative return on equity of 104.47% and a negative net margin of 38.72%. During the same quarter in the prior year, the business posted ($0.01) earnings per share. As a group, analysts expect that Calliditas Therapeutics AB will post 0.29 EPS for the current fiscal year.

Institutional Investors Weigh In On Calliditas Therapeutics AB (publ)

Institutional investors have recently added to or reduced their stakes in the stock. Optiver Holding B.V. acquired a new position in Calliditas Therapeutics AB (publ) during the fourth quarter worth $25,000. Tower Research Capital LLC TRC increased its stake in shares of Calliditas Therapeutics AB (publ) by 1,270.2% during the third quarter. Tower Research Capital LLC TRC now owns 3,357 shares of the company’s stock worth $51,000 after purchasing an additional 3,112 shares in the last quarter. Jane Street Group LLC increased its stake in shares of Calliditas Therapeutics AB (publ) by 7.6% during the third quarter. Jane Street Group LLC now owns 12,491 shares of the company’s stock worth $191,000 after purchasing an additional 886 shares in the last quarter. Finally, Deutsche Bank AG raised its position in shares of Calliditas Therapeutics AB (publ) by 26.5% during the 1st quarter. Deutsche Bank AG now owns 90,509 shares of the company’s stock worth $2,170,000 after purchasing an additional 18,978 shares during the last quarter. Institutional investors and hedge funds own 2.83% of the company’s stock.

Calliditas Therapeutics AB (publ) Company Profile

Calliditas Therapeutics AB (publ), a commercial-stage specialty pharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy.